Extracts of Periplaneta americana alleviate hepatic fibrosis by affecting hepatic TGF-β and NF-κB expression in rats with pig serum-induced liver fibrosis
Abstract
Introduction. Liver fibrosis is caused by continuous wound healing responses to various harmful stimuli, including viral infection, drugs, alcohol, and autoimmune liver disease. The purpose of this study was to examine the effects of extracts of Periplaneta americana (EPA) in rats with pig serum-induced liver fibrosis to preliminarily assess the antifibrotic effect of EPA. Material and methods. Seventy rats were randomly divided into 7 groups (10 rats in each group): HC, the healthy control group; FC, the fibrotic control group; TL, low-dose EPA treatment group group; TM, medium-dose EPA group; TH, high-dose EPA treatment group; TC1, Panax notoginseng/Salvia mitiorrhiza treatment control group 1; TC2, colchicine treatment control group 2. TC1 and TC2 were used as the positive control to demonstrate the difference between EPA and the effects of other compounds. The liver fibrosis model was induced by intraperitoneal injection of 0.5 mL pig serum twice a week for 13 weeks in all groups except for the HC group. The hepatic fibrosis model was established at the 7th week, and followingly, the corresponding compounds were administered once a day in all groups for 6 weeks. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity was determined in rat blood serum. We also measured liver fibrosis-related serum markers, including hyaluronic acid (HA), laminin (LN), type III pre-collagen (PC-III) and type IV collagen (IV-C). Hematoxylin and eosin (H&E) and Masson stainings were used to assess liver morphology and determine the stage of fibrosis. Immunohistochemistry was used to detect the protein expression of NF-κB, α-smooth muscle actin (α-SMA), transforming growth factor-β1 (TGF-β1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in rat liver tissue. Results. Compared with that of the HC group, the liver tissue of the FC group presented obvious liver damage and collagen deposition. The serum levels of ALT, AST, HA, LN, PC-III and IV-C and the expression of NF-κB, α-SMA, TGF-β1 and TIMP-1 in the FC group were significantly higher than those in the HC group, the EPA treatment groups, the TC1 group and the TC2 group (P < 0.01). The levels of serum ALT, AST, HA, LN, PC-III and IV-C and the expression of α-SMA, NF-κB, TGF-β1 and TIMP-1 in the TL, TC1 and TC2 groups were significantly higher than those TM and TH groups (P < 0.05). EPA treatment significantly improved liver function, decreased collagen deposition and reversed the pathological changes related to liver fibrosis. Conclusions. We found that EPA could reduce liver inflammation, suppress liver cell degeneration and necrosis, and reduce the formation of liver fibrous tissue. Its mechanism might be associated with inhibiting the expression of TGF-β1, TIMP-1, NF-κB and α-SMA to block signal transduction pathways in the hepatic fibrosis process. Therefore, EPA, as a traditional Chinese medicine, might be potentially used to prevent and treat hepatic fibrosis in the future. However, further more experiments are necessary to verify its effectiveness and possible signaling pathways.
Keywords: Ratpig-serum hepatic fibrosisPeriplaneta americanaNF-κBα-SMATGF-β1TIMP-1IHC
References
- Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019; 97(3): 230–238.
- Naik N, Madani A, Esteva A, et al. Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains. Nat Commun. 2020; 11(1): 5727.
- Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019; 156(8): 2230–2241.e11.
- Fitzpatrick E. Non-alcoholic fatty liver disease. Oxford Medicine Online. 2018.
- Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020; 9(4).
- Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol. 2009; 25(3): 223–229.
- Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the third AASLD single topic conference. Hepatology. 2007; 45(1): 242–249.
- Huang M, Kim HG, Zhong X, et al. Sestrin 3 protects against diet-induced nonalcoholic steatohepatitis in mice through suppression of transforming growth factor β signal transduction. Hepatology. 2020; 71(1): 76–92.
- Wan Y, Wu YL, Lian LH, et al. The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-κB nuclear protein translocation. Chem Biol Interact. 2012; 195(3): 215–223.
- Li D, Li Wu, Chen Y, et al. Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fibrosis in rats. Acta Biochim Biophys Sin (Shanghai). 2018; 50(5): 491–498.
- Li W, Duan L, He G, et al. [Prevention of CC14-induced liver fibrosis by Periplaneta americana extract]. Zhonghua Gan Zang Bing Za Zhi. 2009; 17(12): 948–950.
- Li W, Duan L, He G, et al. Effects of Periplaneta americana extract on experimental liver fibrosis. Lishizhen Medicine and Materia Medica Research. 2010; 21(5): 1137–1138.
- Iezzoni JC. Diagnostic histochemistry in hepatic pathology. Semin Diagn Pathol. 2018; 35(6): 381–389.
- Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994; 20(1): 15–20.
- Liu L, Li W, Ma D, et al. Effect of American cockroach extract on NF-κB andα-SMA expression in CCl4 caused liver fibrosisrat model. Chongqing Medicine. 2014; 00(17): 015.
- Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991; 13(3): 372–374.
- Ebrahimi H, Naderian M, Sohrabpour AA. New concepts on pathogenesis and diagnosis of liver fibrosis; a review article. Middle East J Dig Dis. 2016; 8(3): 166–178.
- Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014; 20(23): 7312–7324.
- Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. World J Gastroenterol. 2013; 19(9): 1359–1371.
- Ding J, Yu J, Wang C, et al. Ginkgo biloba extract alleviates liver fibrosis induced by CCl in rats. Liver Int. 2005; 25(6): 1224–1232.
- Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5): 1572–1585.
- Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4: 2823.
- Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013; 3(4): 1473–1492.
- Wells RG, Schwabe RF. Origin and function of myofibroblasts in the liver. Semin Liver Dis. 2015; 35(2): e1.
- Luk JM, Wang X, Liu P, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int. 2007; 27(7): 879–890.
- Li CY, Chen YJ, Li SN, et al. Anti-hepatic fibrosis effects research on serum containing extracts of Periplaneta americana in vitr o]. Zhong Yao Cai. 2013; 36(5): 707–711.
- Li D, Li Wu, Chen Y, et al. Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fibrosis in rats. Acta Biochim Biophys Sin (Shanghai). 2018; 50(5): 491–498.
- Shi W, An Li, Zhang J, et al. extract ameliorates lipopolysaccharide-induced liver injury by improving mitochondrial dysfunction via the AMPK/PGC-1α signaling pathway. Exp Ther Med. 2021; 22(4): 1138.
- Zou Y, Zhang M, Zeng Di, et al. Extracts accelerate liver regeneration a complex network of pathways. Front Pharmacol. 2020; 11: 1174.
- Wang K, Lin B, Brems JJ, et al. Hepatic apoptosis can modulate liver fibrosis through TIMP1 pathway. Apoptosis. 2013; 18(5): 566–577.
- Yang P, Niu Y. TGF-β1/Smad signaling pathway in tissue fibrosis:research advances. International Journal of Pharmaceutical Research. 2019; 46(10): 738–744.
- Decologne N, Kolb M, Margetts PJ, et al. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J Immunol. 2007; 179(9): 6043–6051.
- Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007; 13(11): 1324–1332.
- Liang Q, Lin Q, Li Y, et al. Effect of SIS3 on extracellular matrix remodeling and repair in a lipopolysaccharide-induced ARDS rat model. J Immunol Res. 2020; 2020: 6644687.
- Cheng K, Yang N, Mahato RI. TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm. 2009; 6(3): 772–779.
- Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002; 115(Pt 19): 3719–3727.
- Stetler-Stevenson WG. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev. 2008; 27(1): 57–66.
- Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88(1): 125–172.
- Fowell AJ, Collins JE, Duncombe DR, et al. Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation. Biochem Biophys Res Commun. 2011; 407(2): 277–282.
- Rippe RA, Brenner DA. From quiescence to activation: gene regulation in hepatic stellate cells. Gastroenterology. 2004; 127(4): 1260–1262.
- Zhang Y, Xu N, Xu J, et al. E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology. 2014; 60(3): 919–930.
- Foo NP, Lin SH, Lee YH, et al. α-Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology. 2011; 282(1-2): 39–46.
- Kong D, Zhang F, Zhang Z, et al. Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential. Biomed Pharmacother. 2013; 67(3): 246–250.
- Park JS, Oh Y, Park YJ, et al. Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Nat Commun. 2019; 10(1): 1128.
- Dunphy G, Flannery SM, Almine JF, et al. Non-canonical activation of the DNA sensing adaptor STING by ATM and IFI16 mediates NF-κB signaling after nuclear DNA damage. Mol Cell. 2018; 71(5): 745–760.e5.
- Iida Y, Ciechanover A, Marzese DM, et al. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. Clin Cancer Res. 2017; 23(16): 4831–4842.
- Song W, Xu J, Xu R, et al. Expression and distribution of NF-κB in experimental hepatic fibrosis. Chinese Journal of Pathophysiology. 2010; 26(1): 12–16.
- Khattar E, Maung KZ, Chew CLi, et al. Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy. Nat Commun. 2019; 10(1): 5349.
- Li L, Wei J, Mallampalli RK, et al. TRIM21 mitigates human lung microvascular endothelial cells' inflammatory responses to LPS. Am J Respir Cell Mol Biol. 2019; 61(6): 776–785.
- Scirpo R, Fiorotto R, Villani A, et al. Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium. Hepatology. 2015; 62(5): 1551–1562.
- Yu Y, Luo Y, Fang Z, et al. Mechanism of sanguinarine in inhibiting macrophages to promote metastasis and proliferation of lung cancer via modulating the exosomes in A549 cells. Onco Targets Ther. 2020; 13: 8989–9003.
- Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007; 46(2): 590–597.
- Pillon NJ, Azizi PM, Li YE, et al. Palmitate-induced inflammatory pathways in human adipose microvascular endothelial cells promote monocyte adhesion and impair insulin transcytosis. Am J Physiol Endocrinol Metab. 2015; 309(1): E35–E44.
